| Stage | MYRG | % of rev | ECG | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.3B | 100.00% | $1.2B | 100.00% | MYRG ×1.02 |
| Gross profit | $171M | 13.60% | $183M | 14.85% | ECG +1.3pp |
| Operating income | $85M | 6.76% | $112M | 9.08% | ECG +2.3pp |
| Pre-tax income | $82M | 6.54% | $110M | 8.93% | ECG +2.4pp |
| Net income | $60M | 4.77% | $84M | 6.81% | ECG +2.0pp |
| Stage | MYRG | ECG | Gap · A − B |
|---|---|---|---|
| Revenue | $1.3B100.00% | $1.2B100.00% | MYRG ×1.02 |
| Gross profit | 13.60%$171M | 14.85%$183M | ECG +1.3pp |
| Operating income | 6.76%$85M | 9.08%$112M | ECG +2.3pp |
| Pre-tax income | 6.54%$82M | 8.93%$110M | ECG +2.4pp |
| Net income |
| 4.77%$60M |
| 6.81%$84M |
| ECG +2.0pp |
None
No disclosed counterparties: MYRG.